AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05092269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as a SC injection.
Study NCT06572423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized ultrafractionated stereotactic adaptive radiotherapy
Description: PULSAR is a radiation therapy regimen that uses a limited number of fairly large dose pulses while adjusting to specific anatomic and/or biological changes which may occur during the course of the treatment.
Study NCT06572423 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volume Modulated Arc Therapy
Description: Use HyperArc technology
Study NCT06572423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT simulation for radiation planning
Study NCT06572423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT06572423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06572423 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo standard of care
Study NCT06572423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: University of Washington Quality of Life Scale, Version 4
Description: Complete questionnaire
Study NCT06572423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy-Head & Neck
Description: Complete questionnaire
Study NCT04865770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Study NCT04865770 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: Placebo (Semaglutide) given subcutaneously (sc, under the skin) once weekly. Dose gradually increased over 8 weeks from 0.25 to 1.0 mg. The study will last for about 1 year.
Study NCT05909397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 (PF-07850327)
Description: Pharmaceutical form: Tablets. Route of Administration: Oral
Study NCT05909397 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules. Route of Administration: Oral.
Study NCT05909397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Pharmaceutical form: Capsules. Route of Administration: Orally
Study NCT05909397 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Pharmaceutical form: Capsules. Route of Administration: Oral.
Study NCT04768842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study NCT04958330 — intervention group
Intervention type: PROCEDURE
Intervention: lateral prostate capsule sparing
Description: When resect the bladder and prostate, the lateral prostate capsule will be preserved.
Study NCT05535543 — intervention group
Intervention type: PROCEDURE
Intervention: Prone Positioning
Description: Patients will be turned to prone position and they will be left in prone position for a duration of at least 16 hours to a maximum of 24 hours. This duration is recommended by the ARDS guidelines.
Study NCT05190224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization of the deep peroneal, posterior tibial and medial medial and lateral dorsocutaneous nerves.
Description: In lateral decubitus the patient with the help of the clinician will perform neuromeningeal mobilization of the posterior tibial dorsocutaneous lateral, intermediate and medial nerves and deep peroneal nerve too.
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiandrogen Therapy
Description: Given ADT
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given ADT
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO
Study NCT04947254 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04947254 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT04947254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT04947254 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04947254 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT05774483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Node Biopsy
Description: The Sentinel node will be localized after injecting peritumoral nano colloid followed by dynamic lymphoscintigraphy and SPECT localization. Methylene blue or indocyanine green may be used but not mandatory as an adjunct for lymphoscintigraphy for node localization. Intraoperatively the node will be identified using a hand-held gamma probe. The sentinel node will be processed on a frozen section, histopathological processing with serial step sectioning, and immunohistochemistry. If reported as metastatic, then a single-stage or second-stage completion neck dissection will be performed.
Study NCT05774483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited Elective Neck Dissection
Description: Patients who are allocated to the limited END arm will undergo dissection of level I, IIa and III/IV nodes sparing level IIb. Level IIa will be subjected to a frozen section and if reported as metastatic will mandate clearance of level IIb.
Study NCT05164302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, we use press tack needles to perform auricular acupuncture.
Study NCT04739462 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Platform
Description: All participants randomized to the intervention group will receive 2-4 informational texts each week and will also receive interactive health screening questions throughout enrollment. A participant will also receive appointment reminder texts. All SMS text messages will be transmitted through a local organization known as The Medical Concierge Group (TMCG) via an electronic system that allows for bulk messaging. TMCG also staffs a 24-hour call line for those using TMCG services to call in for medical related questions. This call line is staffed by doctors and nurses; SMS Maama participants randomized to the interventional group will be able to access this call line free of charge as part of their enrollment in SMS Maama.
Study NCT05672212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANI (Analgesia/Nociception Index) monitoring
Description: Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
Study NCT05672212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard monitoring
Description: Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
Study NCT05672212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil
Study NCT05672212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil
Study NCT05158101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT06487598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inj insulin to one group
Description: One group- only inj insulin for 3 months.
Study NCT06487598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj Insulin with Tab Nisha-Amalaki 500 mg twice a day
Description: second group- Inj Insulin with Tab Nisha-Dhatri 500 mg twice a day
Study NCT06355934 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: not applicable, this is an observational retrospective data analysis study; no interventions in the study
Study NCT04947137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
Study NCT05959785 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Basic and light cervical mobilization exercises
Description: This group of exercises will be made up of a series of cervical mobilization exercises that are performed without pain, smooth, controlled by the patients, and without forcing the angulations. They are performed seated, with the arms extended along the body and forearms and hands resting on the legs. The chair must be firm and comfortable. Head movements to the right and left, right and left lateral flexion of the cervical region, cervical flexion and extension will be performed. This exercise will be performed for 5 minutes 3 times a day and beginning in the first 24 postoperative hours.
Study NCT05959785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal or diaphragmatic breathing exercises
Description: The first abdominal or diaphragmatic breathing exercises will be carried out in a lying position, with the back well supported on a comfortable and firm surface, and with hips and knees flexed and feet supported. The patients take deep breaths, taking air raising the abdomen towards the ceiling, without raising the back from the horizontal plane. During expiration the navel will lower posteriorly and rise towards the thoracic region. For the second abdominal or diaphragmatic breathing exercise, the patient is seated on a firm and comfortable surface, with hips and knees flexed and feet supported. An inspiratory movement will be made in which the patient's navel will be moved outward, away from the spine. During expiration, the navel will go in the direction of the patient's spine and will rise in the direction of the thorax.
Study NCT04914884 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: intraocular fluid detection
Description: This study mainly verified the use of molecular biology technology to detect the changes of VCAM, ICAM-1 and other cytokines, bacteria, viruses, fungi, Toxoplasma gondii IgG in patients' intraocular fluid, including aqueous humor and vitreous humor, so as to timely judge the etiology and progress of endophthalmitis, and provide reference for diagnosis and treatment.
Study NCT04448834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: liposomal vincristine 2.25 mg/m2 weekly x 3 per cycle (weeks 3-5 in cycle 1 and 2-4 in subsequent cycles)
Study NCT05711056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sociobehavioral Intervention
Description: Utilizes two primary evidence-based strategies:~* Delivering OUD consultation via telemedicine, which has been demonstrated to be a safe and effective means for initiating MOUD with buprenorphine; and,~* Incorporating psychosocial support in the form of PRC, whose involvement in patient care is associated with increased treatment retention and MOUD initiation.
Study NCT05655286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% SDF treatment
Description: Children with active caries will receive 38% silver diamine fluoride treatment
Study NCT05655286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: not to rinse for at least 30 minutes after SDF treatment
Description: After receiving 38% silver diamine fluoride treatment, Children will be asked not to rinse their mouths for at least 30 minutes.
Study NCT05655286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rinse mouth immediately after SDF treatment
Description: After receiving 38% silver diamine fluoride treatment, Children will be asked to rinse their mouths immediately.
Study NCT06226805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-031
Description: Solution for injection
Study NCT06226805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride for injection
Study NCT05556096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ALXN1720
Description: Combination product consisting of syringe prefilled with ALXN1720.
Study NCT05556096 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination product consisting of syringe prefilled with placebo.
Study NCT06760065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan Hydrochloride tablets + high dose amoxicillin
Description: Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.
Study NCT06760065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Susceptibility-Guided Quadruple Therapy
Description: Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
Study NCT06767293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-InTERACT Parenting Intervention (I2P) and coaching sessions
Description: Online learning sessions for parents of preterm children
Study NCT06767293 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions
Description: Online microlearning sessions for parents of preterm children
Study NCT06767293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Internet Resources
Description: control condition
Study NCT06767358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine hydrochloride
Description: Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour
Study NCT06767358 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Normal saline placebo infusion
Study NCT06768606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Social-emotional learning curriculum
Description: EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context. The STEM Academy program will implement a shortened version of the social-emotional learning curriculum to meet their timelines.
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 4mg
Description: Oral tablet containing 4 mg of ALKS 2680 for once daily administration
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 6mg
Description: Oral tablet containing 6 mg of ALKS 2680 for once daily administration
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 8mg
Description: Oral tablet containing 8 mg of ALKS 2680 for once daily administration
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 10mg
Description: Oral tablet containing 10 mg of ALKS 2680 for once daily administration
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 14mg
Description: Oral tablet containing 14 mg of ALKS 2680 for once daily administration
Study NCT06767683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 18mg
Description: Oral tablet containing 18 mg of ALKS 2680 for once daily administration
Study NCT06768021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided visualization and standardized pre-sedation instructions
Description: One arm will receive standardized pre-sedation instructions, as well as one-minute guided visualization.
Study NCT06768021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized pre-sedation instructions only
Description: One arm will receive standardized pre-sedation instructions only.
Study NCT06767371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
Description: Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
Study NCT06767371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
Description: Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
Study NCT06767371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Teeth with irreversible pulpitis
Description: Teeth with irreversible pulpitis to be treated with conventional root canal treatment
Study NCT06769139 — intervention group
Intervention type: OTHER
Intervention: Red blood cell exchange
Description: Red blood cell exchange manual exchange and automatized exchange
Study NCT06767410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Intervention
Description: The intervention is distinguished by its multidomain approach combining cognitive, social, and musical activities through choir participation, targeting holistic cognitive and emotional benefits, unlike active controls (general activities) and passive controls (no activities).
Study NCT06767410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General activities
Description: Participants will carry out a series of physical, manual and/or intellectual activities (e.g., horticulture, physical activities, theatre, learning programs etc.) but not musical activities
Study NCT06769087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal
Description: A urinary catheter is removed immediately after surgery and before general anesthesia wears off in the operating room.
Study NCT06769087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: urinary catheter removal within postoperative 1day
Description: The urethral catheter will be removed in the ward within 1 day after surgery (within 24 hours after surgery).
Study NCT06766253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMA-TULIP
Description: Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
Study NCT06766253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMA-TULIP
Description: Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
Study NCT05242471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study NCT05242471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as subcutaneous injection.
Study NCT05242471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.
Study NCT05242471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.
Study NCT05622955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Empowered Endometriosis Pain Support (PEEPS)
Description: The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
Study NCT06525896 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSSD
Description: A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.
Study NCT06525896 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSSD
Description: A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
Study NCT06450444 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PRIMUS
Description: The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.